Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ IL-2 β/γ Clinical Program

NEXT STORY
Ascendis Pharma A/S Announces Upcoming Investor Presentations
PREV STORY
iBio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Chembio Diagnostics Receives WHO Prequalification Approval for HIV Self-Test

author_avatar
NASDAQ Market News

Cellceutix to Present at Biotech Showcase 2017; Brilacidin for Oral Mucositis Nears Interim Results

BEVERLY, Mass., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a ...

author_avatar
NASDAQ Market News

Idera to Host Investor Conference Call on Monday, September 11, 2017 at 9:00 A.M. E.T.

CAMBRIDGE, Mass. and EXTON, Pa., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ...

author_avatar
NASDAQ Market News